Literature DB >> 21368777

Maternal serum insulin-like growth factor-binding protein-3 (IGFBP-3) at 11-13 weeks in preeclampsia.

S Sifakis1, R Akolekar, D Kappou, N Mantas, K H Nicolaides.   

Abstract

The objective of this study was to determine if the maternal serum concentration of insulin-like growth factor-binding protein-3 (IGFBP-3) at 11-13 week's gestation is altered in pregnancies that subsequently develop preeclampsia (PE). Maternal serum concentration of IGFBP-3, pregnancy-associated plasma protein-A (PAPP-A) and uterine artery pulsatility index (PI) were measured in 60 cases that developed PE, including 20 that developed early-PE requiring delivery before 34 weeks, and compared with 120 unaffected controls. In the unaffected pregnancies, the median multiple of the normal median (MoM) values of serum IGFBP-3, PAPP-A and uterine artery PI were 1.0 MoM. In late-PE, but not in early-PE, serum IGFBP-3 was significantly increased (1.16 and 1.06 MoM, respectively), whereas in early-PE, but not in late-PE, uterine artery PI was increased (1.41 and 1.11 MoM, respectively) and serum PAPP-A was decreased (0.53 and 0.87 MoM, respectively). In the PE group, there was no significant association between IGFBP-3 and either uterine artery PI (P=0.775) or maternal serum PAPP-A (P=0.275). First-trimester serum IGFBP-3 is increased in pregnancies that subsequently develop late-PE in a mechanism that is unrelated to impaired placentation, as reflected in uterine artery PI and serum PAPP-A.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21368777     DOI: 10.1038/jhh.2011.16

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  3 in total

Review 1.  Insulin-like growth factors in embryonic and fetal growth and skeletal development (Review).

Authors:  Georgios D Agrogiannis; Stavros Sifakis; Efstratios S Patsouris; Anastasia E Konstantinidou
Journal:  Mol Med Rep       Date:  2014-05-21       Impact factor: 2.952

2.  Validation of serum biomarkers derived from proteomic analysis for the early screening of preeclampsia.

Authors:  Aggeliki Kolialexi; Dimitrios Gourgiotis; George Daskalakis; Antonis Marmarinos; Alexandra Lykoudi; Danai Mavreli; Ariadni Mavrou; Nikolas Papantoniou
Journal:  Dis Markers       Date:  2015-01-05       Impact factor: 3.434

3.  Early detection of maternal risk for preeclampsia.

Authors:  B Mikat; A Gellhaus; N Wagner; C Birdir; R Kimmig; A Köninger
Journal:  ISRN Obstet Gynecol       Date:  2012-07-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.